FDA approves New Therapy Aimed at a New Target in Esophageal Cancer at the GE Junction
The Food and Drug Administration (FDA) has approved Zolbetuximab (Vyloy) as a first-line treatment for patients with advanced HER2* [...]
Study finds Regimen that doesn’t include Radiation is Better than current Standard
A German study finds a 30% reduction in the risk of death among Esophageal Adenocarcinoma patients who were treated [...]
Funding Available for Esophageal Cancer Prevention & Treatment Research
Millions are available for research into the prevention, detection, diagnosis, treatment, and survival of Esophageal Cancer through the Department [...]
Powerful Tool to Catch Esophageal Cancer Before It Starts
A newly released study of the benefits of the EsoGuard® Esophageal DNA test says it is a powerful screening [...]
Five-Year Data on Immunotherapy for Advanced Esophageal Cancer Shows Tripling of Survival Rate
At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, long-term data from [...]
New Discovery: Inherited Gene Mutation linked to Esophageal Adenocarcinoma
A breakthrough by researchers at Case Western Reserve has led to the discovery of an Inherited Gene Mutation linked to [...]
Potential “Game Changer” for Esophageal Cancer Patients: Vitamin D can Play a Significant Role in Survival for Many Patients with Both Major Types of Esophageal Cancer
A recent analysis found that the use of Vitamin D supplements significantly reduced the risk of relapse or death in [...]
Genetic Game-Changer?
A new study finds that 9% of all Esophageal Adenocarcinoma (EAC) patients have mutations in cancer-predisposing genes, potentially opening the [...]
New, Free Clinical Trials Matching
ECAN is proud to launch a new, personalized service to match Esophageal Cancer patients with the best Clinical Trial [...]
Beta Blockers to Improve Immunotherapy Response
Less than a third of Esophageal Cancer Patients Respond to Immunotherapy. Could a Medication Commonly Used to Treat Anxiety [...]